JP2016053040A5 - - Google Patents

Download PDF

Info

Publication number
JP2016053040A5
JP2016053040A5 JP2015201153A JP2015201153A JP2016053040A5 JP 2016053040 A5 JP2016053040 A5 JP 2016053040A5 JP 2015201153 A JP2015201153 A JP 2015201153A JP 2015201153 A JP2015201153 A JP 2015201153A JP 2016053040 A5 JP2016053040 A5 JP 2016053040A5
Authority
JP
Japan
Prior art keywords
relaxin
risk
mortality
composition
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015201153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016053040A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016053040A publication Critical patent/JP2016053040A/ja
Publication of JP2016053040A5 publication Critical patent/JP2016053040A5/ja
Pending legal-status Critical Current

Links

JP2015201153A 2008-05-16 2015-10-09 急性心不全に伴う呼吸困難のリラキシンによる治療 Pending JP2016053040A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US61/127,889 2008-05-16
US19054508P 2008-08-28 2008-08-28
US61/190,545 2008-08-28
US20124008P 2008-12-08 2008-12-08
US61/201,240 2008-12-08
US16433309P 2009-03-27 2009-03-27
US61/164,333 2009-03-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014165276A Division JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療

Publications (2)

Publication Number Publication Date
JP2016053040A JP2016053040A (ja) 2016-04-14
JP2016053040A5 true JP2016053040A5 (enExample) 2016-07-07

Family

ID=40834101

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011509783A Expired - Fee Related JP5651586B2 (ja) 2008-05-16 2009-05-15 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2012200728A Expired - Fee Related JP5638044B2 (ja) 2008-05-16 2012-09-12 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2014165276A Expired - Fee Related JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2015201153A Pending JP2016053040A (ja) 2008-05-16 2015-10-09 急性心不全に伴う呼吸困難のリラキシンによる治療

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2011509783A Expired - Fee Related JP5651586B2 (ja) 2008-05-16 2009-05-15 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2012200728A Expired - Fee Related JP5638044B2 (ja) 2008-05-16 2012-09-12 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2014165276A Expired - Fee Related JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療

Country Status (30)

Country Link
US (7) US8053411B2 (enExample)
EP (2) EP2288373B1 (enExample)
JP (4) JP5651586B2 (enExample)
CN (3) CN103212063B (enExample)
AR (1) AR071810A1 (enExample)
AU (1) AU2009246114B2 (enExample)
BR (1) BRPI0913011A2 (enExample)
CA (1) CA2724540C (enExample)
CR (1) CR11749A (enExample)
CY (1) CY1116925T1 (enExample)
DK (1) DK2288373T3 (enExample)
EA (2) EA022948B1 (enExample)
ES (1) ES2546287T3 (enExample)
GB (2) GB2462221B (enExample)
HK (1) HK1202054A1 (enExample)
HR (1) HRP20150845T1 (enExample)
HU (1) HUE025483T2 (enExample)
IL (3) IL208992A (enExample)
MA (1) MA32389B1 (enExample)
MX (1) MX2010012450A (enExample)
MY (2) MY159803A (enExample)
NZ (3) NZ701038A (enExample)
PL (1) PL2288373T3 (enExample)
PT (1) PT2288373E (enExample)
SG (2) SG191587A1 (enExample)
SI (1) SI2288373T1 (enExample)
TW (1) TWI386202B (enExample)
UA (1) UA99953C2 (enExample)
WO (1) WO2009140659A2 (enExample)
ZA (1) ZA201007449B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140659A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating dyspnea associated with acute heart failure
MX336145B (es) * 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
US20130053318A1 (en) 2010-03-10 2013-02-28 Parry Laura Modulating aquaporins with relaxin
EP2601532B1 (en) * 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9382305B2 (en) * 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
ES2929283T3 (es) 2012-05-04 2022-11-28 Us Health Moduladores del receptor de relaxina 1
EA030354B1 (ru) * 2012-10-26 2018-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ уменьшения диспноэ у пациента с острой сердечной недостаточностью
US9884039B2 (en) 2013-04-05 2018-02-06 Scpharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SG11201605273XA (en) * 2014-02-03 2016-08-30 Novartis Ag Filters for infusion sets
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906019B1 (en) 2019-01-04 2025-11-26 SQ Innovation AG Pharmaceutical compositions of furosemide
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
CA3128033A1 (en) 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
AU2023332056A1 (en) 2022-08-31 2025-03-13 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
EP0707650B1 (en) * 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
WO1995003822A2 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
DE69624925T2 (de) 1995-08-15 2003-09-04 Connetics Corp., Palo Alto Verwendung von relaxin zur stimulierung der angiogenese
DE60128540T2 (de) 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2006075819A1 (en) * 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
AU2008273813B2 (en) 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
MX336145B (es) 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
WO2009140659A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating dyspnea associated with acute heart failure

Similar Documents

Publication Publication Date Title
MY187047A (en) Selective pyy compounds and uses thereof
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
EA201690962A1 (ru) Составы
JP2015057451A5 (enExample)
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
TN2017000270A1 (en) Use of prg4 as an anti-inflammatory agent
JP2016518337A5 (enExample)
EA201500552A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
UA111599C2 (uk) Композиція каспофунгіну
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
JP2013166781A5 (enExample)
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112015007592A2 (pt) composições de enalapril
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
JP2015516452A5 (enExample)
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
NI201200008A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st
MD4763B1 (ro) Compoziţie farmaceutică
JP2015516451A5 (enExample)
JP2015516450A5 (enExample)